Tadalafil, (6R,12aS)-(CAS: 171596-27-3)

Regulatory guidelines for Tadalafil include adherence to the Chemical Abstracts Service (CAS) registry number 171596-27-3. It is subject to the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulations in the EU, which require manufacturers and importers to register substances and provide safety data sheets (SDS). Additionally, the U.S. Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) have specific requirements for the handling, storage, and disposal of Tadalafil, including GHS classification for health and environmental hazards.

In synthesis, alternatives to Tadalafil include using related PDE5 inhibitors such as sildenafil, vardenafil, or avanafil. These alternatives can be used as starting materials or as intermediates in the synthesis of Tadalafil. Isomers and analogs, such as the 6R,12aS-isomer, are also relevant in the synthesis of Tadalafil, providing flexibility in the manufacturing process.

The market for Tadalafil is characterized by a focus on its therapeutic applications, particularly in erectile dysfunction and benign prostatic hyperplasia. Research trends include ongoing studies on its potential uses in cardiovascular diseases and other conditions. Market trends show a stable demand, with price and revenue growing steadily. Emerging research is exploring the compound's mechanism of action and potential for personalized medicine approaches.

Waste containing Tadalafil should be collected in appropriate containers and handled according to environmental protection standards. Incineration or professional waste disposal services are recommended to ensure safe disposal. Environmental precautions include minimizing the release of Tadalafil into the environment, and proper labeling and documentation of waste disposal to comply with local regulations. It is crucial to follow safe handling procedures to prevent exposure and ensure compliance with regulatory requirements.